{
    "2021-08-16": [
        [
            {
                "time": "",
                "original_text": "大参林：监事及高管人员尚未减持，减持计划时间已过半",
                "features": {
                    "keywords": [
                        "大参林",
                        "监事",
                        "高管",
                        "减持",
                        "计划"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "大参林(603233.SH)多位监事及高管尚未减持 减持时间过半",
                "features": {
                    "keywords": [
                        "大参林",
                        "监事",
                        "高管",
                        "减持",
                        "时间过半"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：医疗服务三问三答 何时会出现板块性机会？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "医疗服务",
                        "板块性机会"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：关注CXO新秀 重点推荐皓元医药、诺泰生物等",
                "features": {
                    "keywords": [
                        "医药生物",
                        "CXO",
                        "皓元医药",
                        "诺泰生物"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}